Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MYO5B Deficiency Is Associated with Altered MUC13 Localization and DMBT1 Accumulation in Intestinal Epithelial Cells.

American journal of physiology. Gastrointestinal and liver physiology·2026
Same author

Saffron Alters Microbial Amino Acid Metabolism and Neurotransmitter Production in a Defined Gut Consortium.

Food science & nutrition·2026
Same author

A pilot study of maternal vitamin D status and its association with breast milk and infant gut metabolites.

Physiological reports·2026
Same author

<i>Akkermansia muciniphila</i> Selectively Reshapes Small Intestinal Cell Populations.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society·2026
Same author

KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

Cancer research·2026
Same author

Macrophage Heterogeneity in Liver Ischemia-Reperfusion Injury.

Research square·2026
Same journal

Whole-Embryo 3D Quantification Reveals Conserved Topological Design and Scaling of Germ Layers in Xenopus.

bioRxiv : the preprint server for biology·2026
Same journal

scRNA-seq and genomics analyses reveal key mechanisms of inverted papilloma-associated sinonasal squamous cell carcinoma malignant transformation.

bioRxiv : the preprint server for biology·2026
Same journal

M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.

bioRxiv : the preprint server for biology·2026
Same journal

A human-specific genetic modifier reconfigures large-scale cortical network dynamics underlying behavioral performance.

bioRxiv : the preprint server for biology·2026
Same journal

<i>Staphylococcus aureus</i> uses a eukaryotic-like uridyltransferase to make UDP-GlcNAc for cell wall synthesis.

bioRxiv : the preprint server for biology·2026
Same journal

Dynamic redistribution of eIF4F controls cap-dependent translation initiation.

bioRxiv : the preprint server for biology·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

MUC4-targeted CAR-T Cells Restrain Chemotherapy-resistant Colorectal Cancer.

Avik Chattopadhyay1,2, Erin C O'Connor1,2, Anna M Tingler2,3

  • 1Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.

Biorxiv : the Preprint Server for Biology
|May 13, 2026
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor (CAR) T-cell therapy targeting MUC4 shows promise for treating chemoresistant colorectal cancer (CRC). This MUC4-targeted therapy effectively reduced tumors and improved survival in preclinical models without off-target toxicity.

Keywords:
CAR-T cellChemotherapy-resistantColorectal cancerMUC4Peritoneal metastasis

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Related Experiment Videos

Last Updated: May 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer mortality in young adults.
  • Chemoresistance and metastatic progression limit treatment options for CRC.
  • Aberrant MUC4 overexpression on tumor cells promotes CRC survival, immune evasion, and metastasis.

Purpose of the Study:

  • To evaluate MUC4 as a target for chimeric antigen receptor (CAR) T-cell therapy in colorectal cancer.
  • To assess the efficacy and safety of MUC4 CAR-T cells against chemoresistant and metastatic CRC models.

Main Methods:

  • Engineered MUC4-specific CAR T-cells.
  • Tested MUC4 CAR-T cells against methotrexate-resistant MUC4-expressing CRC cell lines (HT29-MTX, T84) in vitro.
  • Evaluated MUC4 CAR-T cells in vivo using subcutaneous and intraperitoneal CRC mouse models.

Main Results:

  • MUC4 CAR-T cells demonstrated potent killing of MUC4-expressing CRC cells in vitro.
  • MUC4 CAR-T cells delayed tumor growth in subcutaneous models and significantly reduced tumor burden in metastatic models.
  • Improved survival was observed in mice treated with MUC4 CAR-T cells.
  • No off-target toxicities were detected in vivo.

Conclusions:

  • MUC4 is a clinically relevant target for CAR-T cell therapy in colorectal cancer.
  • MUC4 CAR-T cell therapy exhibits significant therapeutic efficacy against invasive and chemoresistant CRC.
  • This therapy holds potential for treating MUC4-expressing solid tumors and addressing unmet clinical needs in CRC.